Literature DB >> 21091250

Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, crossover clinical trial.

Arrigo F G Cicero1, Martina Rosticci, Maddalena Veronesi, Stefano Bacchelli, Enrico Strocchi, Camilla Melegari, Elisa Grandi, Claudio Borghi.   

Abstract

Contrasting data partially support a certain antihypertensive efficacy of lactotripeptides derived from enzymatic treatment of casein hydrolysate. We carried out a randomized, double-blind, crossover clinical study to investigate the antihypertensive efficacy of a short-term treatment with lactotripeptides in Mediterranean subjects with normal or high-normal blood pressure (BP). We consecutively enrolled 55 untreated subjects (men:women = 30:25), 40.3 ± 9.8 years old, with normal or high-normal BP. After 4 weeks of dietary standardization, they were allocated to treatment with a fruit juice containing 3 mg of added Ile-Pro-Pro/Val-Pro-Pro lactotripeptides or with placebo for 4 weeks. After a 4-week washout period, they were then assigned to the alternative treatment for a further period of 4 weeks. Overall, no significant difference has been observed in office BP comparing baseline data with those posttreatment. Repeating the analysis by basal BP level, a mild but significant reduction in systolic BP (-1.7 ± 2.3 mm Hg; t = 3.5, P = .002) has been observed only in subjects with high-normal BP after treatment with lactotripeptides. With regard to 24-hour BP measurement, after lactotripeptide treatment only, the subjects experienced a significant reduction in diurnal diastolic BP (-1.6 ± 5.4 mm Hg; P = .042), diurnal mean BP (-2.1 ± 5.9 mm Hg; P = .19), and 24-hour (-5.4 ± 14.2 mm Hg; P = .011) and diurnal (-7.1 ± 19.2%; P = .014) diastolic BP value measurements relative to normal values. No modification has been observed in relation to plasma renin activity and aldosteronemia. In conclusion, diurnal diastolic BP is significantly reduced by lactrotripeptide supplementation in untreated Mediterranean subjects with normal or high-normal BP. Office systolic BP is reduced only in subjects with high-normal BP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091250     DOI: 10.1089/jmf.2009.0253

Source DB:  PubMed          Journal:  J Med Food        ISSN: 1096-620X            Impact factor:   2.786


  3 in total

Review 1.  Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials.

Authors:  Ágnes A Fekete; D Ian Givens; Julie A Lovegrove
Journal:  Nutrients       Date:  2015-01-20       Impact factor: 5.717

Review 2.  Effect of Casein Hydrolysate on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Shuaishuai Zhou; Teng Xu; Xu Zhang; Junjie Luo; Peng An; Yongting Luo
Journal:  Nutrients       Date:  2022-10-09       Impact factor: 6.706

3.  Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials.

Authors:  Arrigo F G Cicero; Francois Aubin; Veronique Azais-Braesco; Claudio Borghi
Journal:  Am J Hypertens       Date:  2013-01-07       Impact factor: 2.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.